Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Sell-side Focus: NxStage Medical, Inc. (NASDAQ:NXTM) - Markets Daily |
 |
 |
|
The consensus EPS estimate that analysts have on NxStage Medical, Inc. (NASDAQ:NXTM) for the quarter ending 2015-06-30 is $-0.1. The company is next expected to post earnings numbers on or around 2015-08-06. They last posted EPS of $0 for the quarter ending 2015-03-31. This resulted in a surprise factor of 100%. The consensus price target based on 4 analysts covering the stock is currently $21. Out of these projections, the most bullish has the stock at $24 while the most bearish sees the stock at $15 within the next year. When taking a look at the long term growth, analysts have a mean estimate on NxStage Medical, Inc. of $18.33. In comparing to recent history, three months ago the long term growth consensus estimate stood at $18.33. On a recommendation scale of one to five where a one constitutes a Strong Buy and a five constitutes a Strong Sell, NxStage Medical, Inc. (NASDAQ:NXTM) has a rating of 2. This number is based on the average of 4 ratings given by sell-side analysts. About NxStage Medical, Inc. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
